c-Kit

SCFR; CD117

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.

c-Kit Inhibitors

AC710

Cat. No.: HY-13493

AC710 is a potent **PDGFR** inhibitor with K_ds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.



Purity: 99.89%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib

(MP470; HPK 56)

Cat. No.: HY-10206

Amuvatinib (MP470) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: 98.07%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Amuvatinib hydrochloride

(MP470 hydrochloride; HPK 56 hydrochloride)

Cat. No.: HY-10206A

Amuvatinib hydrochloride (MP470 hydrochloride) is an orally bioavailable multi-targeted tyrosine kinase inhibitor with potent activity against mutant **c-Kit**, **PDGFRα**, **Flt3**, **c-Met** and **c-Ret**.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

AST 487

(NVP-AST 487)

Cat. No.: HY-15002

AST 487 is a **RET** kinase inhibitor with IC_{50} of 880 nM, inhibits RET autophosphorylation and activation of downstream effectors, also inhibits **Flt-3** with IC_{50} of 520 nM.



Purity: 99.20%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Avapritinib

(BLU-285)

Cat. No.: HY-101561

Avapritinib (BLU-285) is a highly potent, selective, and orally active **KIT** and **PDGFRA** activation loop mutant kinases inhibitor with IC_{50}s of 0.27 and 0.24 nM for **KIT D816V** and **PDGFRA D842V**, respectively.



Purity: 99.94%
Clinical Data: Launched
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD2932

Cat. No.: HY-18179

AZD2932 is a potent and multi-targeted kinase inhibitor **VEGFR2**, **PDGFβ**, **Flt-3** and **c-Kit** with IC_{50}s of 8, 4, 7 and 9 nM in cell assay, respectively.



Purity: 96.11%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

AZD3229

Cat. No.: HY-112802

AZD3229 is a potent pan-**KIT** mutant inhibitor for the treatment of gastrointestinal stromal tumors.



Purity: 99.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

AZD3229 Tosylate

Cat. No.: HY-112802A

AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.



Purity: 98.54%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

c-Kit-IN-1

Cat. No.: HY-15240

c-Kit-IN-1 is a potent inhibitor of **c-Kit** and **c-Met** with IC_{50}s of <200 nM.



Purity: 98.46%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

c-Kit-IN-2

Cat. No.: HY-128602

c-Kit-IN-2 is a **c-KIT** inhibitor with an IC_{50} of 82 nM, shows superior antiproliferative activities against all the three GIST cell lines, GIST882, GIST430, and GIST48, with GI_{50}s of 3, 1, and 2 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

Cabozantinib

(XL184; BMS-907351) Cat. No.: HY-13016

Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits **VEGFR2**, **c-Met**, **Kit**, **Axl** and **Flt3** with IC_{50}s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.



Purity: 99.96%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Chiauranib

(CS2164) Cat. No.: HY-124526

Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis.



Purity: >98%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

CHMFL-ABL/KIT-155

(CHMFL-ABL-KIT-155) Cat. No.: HY-101034

CHMFL-ABL/KIT-155 (CHMFL-ABL-KIT-155; compound 34) is a highly potent and orally active **type II ABL/c-KIT** dual kinase inhibitor (IC_{50}s of 46 nM and 75 nM, respectively), and it also presents significant inhibitory activities to BLK (IC_{50}=81 nM), CSF1R (IC_{50}=227 nM), DDR1 (IC_{50}=116 nM),...



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CHMFL-KIT-033

Cat. No.: HY-128589

CHMFL-KIT-033 is a potent and selective inhibitor of **c-KIT T670I mutant** for gastrointestinal stromal tumors (GISTs), with an IC_{50} of 0.045 μM.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

DCC-3014

Cat. No.: HY-136256

DCC-3014 is a **c-FMS** (**CSF-IR**) and **c-Kit** dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC_{50}s of <0.01 μM and 0.1-1 μM, respectively.



Purity: 99.08%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Dovitinib

(CHIR-258; TKI258) Cat. No.: HY-50905

Dovitinib (CHIR-258) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/FGFR3**, **VEGFR1/VEGFR2/VEGFR3** and **PDGFRα/PDGFRβ**, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Dovitinib lactate

(CHIR-258 lactate; TKI-258 lactate) Cat. No.: HY-10207

Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: 99.96%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Dovitinib lactate hydrate

(TKI258 lactate hydrate; CHIR-258 lactate hydrate) Cat. No.: HY-B0062

Dovitinib lactate hydrate (TKI258 lactate hydrate) is a multi-targeted tyrosine kinase inhibitor with IC_{50}s of 1, 2, 8/9, 10/13/8, 27/210 nM for **FLT3**, **c-Kit**, **FGFR1/3**, **VEGFR1/2/3** and **PDGFRα/β**, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Flumatinib

(HHGV678) Cat. No.: HY-13904

Flumatinib (HHGV678) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Flumatinib mesylate

(HHGV678 mesylate) Cat. No.: HY-13905

Flumatinib mesylate (HHGV678 mesylate) is an orally available, selective inhibitor of **Bcr-Abl**. Flumatinib mesylate inhibits **c-Abl**, **PDGFRβ** and **c-Kit** with IC_{50}s of 1.2 nM, 307.6 nM and 665.5 nM, respectively.



Purity: 99.97%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 500 mg

HG-7-85-01

Cat. No.: HY-15814

HG-7-85-01 is a type II ATP competitive inhibitor of wild-type and gatekeeper mutations forms of **Bcr-Abl**, **PDGFRα**, **Kit**, and **Src kinases**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib

(STI571; CGP-57148B)

Cat. No.: HY-15463

Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits **BCR/ABL**, **v-Abl**, **PDGFR** and **c-kit** kinase activity.



Purity: 99.54%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

Imatinib D4

(STI571 D4; CGP-57148B D4)

Cat. No.: HY-15463S1

Imatinib D4 (STI571 D4) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Imatinib D8

(STI571 D8; CGP-57148B D8)

Cat. No.: HY-15463S

Imatinib D8 (STI571 D8) is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg

Imatinib Mesylate

(STI571 Mesylate; CGP-57148B Mesylate)

Cat. No.: HY-50946

Imatinib Mesylate (STI571 Mesylate) is a tyrosine kinases inhibitor that inhibits **c-Kit**, **Bcr-Abl**, and **PDGFR** (IC_{50}=100 nM) tyrosine kinases.



Purity: 99.91%
Clinical Data: Launched
Size: 10 mM × 1 mL, 200 mg, 500 mg, 1 g, 5 g

ISCK03

Cat. No.: HY-101443

ISCK03 is a specific **SCF/c-Kit** inhibitor.



Purity: 99.27%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

JNJ-38158471

Cat. No.: HY-18317

JNJ-38158471 is a well tolerated, orally available, highly selective **VEGFR-2** inhibitor, with an IC_{50} of 40 nM. JNJ-38158471 also inhibits **Ret** and **Kit** with IC_{50}s of 180 and 500 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

KG5

Cat. No.: HY-15198

KG5 is an orally active dual **PDGFRβ** and **B-Raf** allosteric inhibitor. KG5 also inhibits **Flt3**, **KIT** and **c-Raf**. KG5 has anticancer, antiangiogenic activities.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ki20227

Cat. No.: HY-10408

Ki20227 is an orally active and highly selective **c-Fms tyrosine kinase (CSF1R)** inhibitor with IC_{50}s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, **VEGFR2** (vascular endothelial growth factor receptor-2), **c-Kit** (stem cell factor receptor) and **PDGFRβ** (platelet-derived growth factor...



Purity: 99.17%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 50 mg

Lenvatinib

(E7080)

Cat. No.: HY-10981

Lenvatinib (E7080) is an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.87%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lenvatinib mesylate

(E7080 mesylate) Cat. No.: HY-10981A

Lenvatinib mesylate (E7080 mesylate), an oral, multi-targeted tyrosine kinase inhibitor that inhibits **VEGFR1-3**, **FGFR1-4**, **PDGFR**, **KIT**, and **RET**, shows potent antitumor activities.



Purity: 99.86%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Linifanib

(ABT-869; AL-39324) Cat. No.: HY-50751

Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of **VEGFR** and **PDGFR** family with IC_{50}s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity.



Purity: 99.72%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

M4205

Cat. No.: HY-132166

M4205 is a **c-KIT** inhibitor, with an IC_{50} of 10 nM for c-KIT V654A. M4205 has high activity on c-KIT mutations in exon 11, 13, 17.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Masitinib

(AB1010) Cat. No.: HY-10209

Masitinib (AB1010) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.94%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Masitinib mesylate

(AB-1010 mesylate) Cat. No.: HY-10209A

Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of **c-Kit** (IC_{50}=200 nM for human recombinant c-Kit). It also inhibits **PDGFRα/β** (IC_{50}s=540/800 nM), **Lyn** (IC_{50}= 510 nM for LynB), **Lck**, and, to a lesser extent, **FGFR3** and **FAK**.



Purity: 99.76%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg

Motesanib

(AMG 706;) Cat. No.: HY-10228

Motesanib is a potent ATP-competitive inhibitor of **VEGFR1/2/3< /b> with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is appr 10-fold more selective for VEGFR than PDGFR and Ret.** .



Purity: 99.99%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Motesanib Diphosphate

(AMG 706 Diphosphate) Cat. No.: HY-10229

Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of **VEGFR1/2/3** with IC_{50}s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.



Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg

Multi-kinase inhibitor 1

Cat. No.: HY-103032

Multi-kinase inhibitor 1 is a potent **multi-kinase** inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of **PDGF-R**, **c-Kit** and **Bcr-abl**.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

OSI-930

Cat. No.: HY-10204

OSI-930 is an orally selective inhibitor of **Kit**, **KDR** and **CSF-1R (c-Fms)** with IC_{50}s of 80 nM, 9 nM and 15 nM, respectively. OSI-930 also moderately inhibits **Flt-1**, **c-Raf**, **Lck** and low activity against **PDGFRα/β**, **Flt-3** and **Abl**. OSI-930 has antitumor activity.



Purity: 98.13%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Pazopanib

(GW786034) Cat. No.: HY-10208

Pazopanib (GW786034) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with IC_{50}s of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.68%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

Pazopanib Hydrochloride

(GW786034 (Hydrochloride)) Cat. No.: HY-12009

Pazopanib Hydrochloride (GW786034 Hydrochloride) is a novel multi-target inhibitor of **VEGFR1**, **VEGFR2**, **VEGFR3**, **PDGFRβ**, **c-Kit**, **FGFR1**, and **c-Fms** with an IC_{50} of 10, 30, 47, 84, 74, 140 and 146 nM, respectively.



Purity: 99.84%
Clinical Data: Launched
Size: 10 mM × 1 mL, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg

PD180970

Cat. No.: HY-103274

PD180970 is a highly potent and ATP-competitive **$p210^{Bcr-Abl}$ kinase** inhibitor, with an IC_{50} of 5 nM for inhibiting the autophosphorylation of **$p210^{Bcr-Abl}$**. PD180970 also inhibits **Src** and **KIT** kinase with IC_{50}s of 0.8 nM and 50 nM, respectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Pexidartinib

(PLX-3397) Cat. No.: HY-16749

Pexidartinib (PLX-3397) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.64%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Pexidartinib hydrochloride

(PLX-3397 hydrochloride) Cat. No.: HY-16749A

Pexidartinib hydrochloride (PLX-3397 hydrochloride) is a potent, orally active, selective, and ATP-competitive **colony stimulating factor 1 receptor (CSF1R or M-CSFR)** and **c-Kit** inhibitor, with IC_{50}s of 20 and 10 nM, respectively.



Purity: 99.95%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 200 mg, 500 mg, 1 g

PLX647

Cat. No.: HY-13838

PLX647 is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, respectively. PLX647 shows selectivity for FMS and KIT over a panel of 400 kinases at a concentration of 1 μM except FLT3 and KDR (IC_{50}s=91 and 130 nM, respectively).



Purity: 99.07%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

PLX647 dihydrochloride

Cat. No.: HY-13838A

PLX647 dihydrochloride is an orally active, highly specific dual **FMS** and **KIT** kinase inhibitor, with IC_{50}s of 28 and 16 nM, reapectively.



Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Ripretinib

(DCC-2618) Cat. No.: HY-112306

Ripretinib (DCC-2618) is an orally bioavailable, selective **KIT** and **PDGFRA** switch-control inhibitor.



Purity: 98.90%
Clinical Data: Launched
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Sitravatinib

(MGCD516; MG-516) Cat. No.: HY-16961

Sitravatinib (MGCD516) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: 99.85%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg

Sitravatinib malate

(MGCD516 malate; MG-516 malate) Cat. No.: HY-16961A

Sitravatinib malate (MGCD516 malate) is an orally bioavailable **receptor tyrosine kinase (RTK)** inhibitor with IC_{50}s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.



Purity: >98%
Clinical Data: Phase 3
Size: 1 mg, 5 mg

SU14813

Cat. No.: HY-10501

SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC_{50}s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 98.90%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

SU14813 maleate

Cat. No.: HY-10501A

SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with **IC_{50}**s of 50, 2, 4, 15 nM for **VEGFR2**, **VEGFR1**, **PDGFRβ** and **KIT**.



Purity: 99.95%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg

Tandutinib

(MLN518; CT53518)

Cat. No.: HY-10202

Tandutinib (MLN518) is a potent and selective inhibitor of the **FLT3** with an **IC_{50}** of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with **IC_{50}**s of 0.17 μM and 0.20 μM, respectively. Tandutinib can be used for acute myelogenous leukemia (AML).



Purity: 99.48%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Tandutinib hydrochloride

(MLN518 hydrochloride; CT53518 hydrochloride)

Cat. No.: HY-10202A

Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the **FLT3** with an **IC_{50}** of 0.22 μM, and also inhibits **c-Kit** and **PDGFR** with **IC_{50}**s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML).



Purity: 98.84%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 50 mg, 100 mg

Telatinib

(Bay 57-9352)

Cat. No.: HY-10527

Telatinib (Bay 57-9352) is an orally active, small molecule inhibitor of **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** with **IC_{50}**s of 6, 4, 15 and 1 nM, respectively.



Purity: 98.72%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Telatinib mesylate

(Bay 57-9352 mesylate)

Cat. No.: HY-10527C

Telatinib mesylate (Bay 57-9352 mesylate) is a potent and orally active **VEGFR2**, **VEGFR3**, **PDGFα**, and **c-Kit** inhibitor with **IC_{50}**s of 6 nM, 4 nM, 15 nM and 1 nM, respectively.



Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Toceranib

(SU11654; PHA 291639E)

Cat. No.: HY-10330

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with **K_i**s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 96.25%
Clinical Data: Launched
Size: 10 mg, 50 mg

Toceranib phosphate

(SU11654 phosphate; PHA 291639E phosphate)

Cat. No.: HY-10330A

Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits **PDGFR**, **VEGFR**, and **Kit** with **K_i**s of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively.



Purity: 98.02%
Clinical Data: Launched
Size: 10 mg, 50 mg

Tyrphostin AG1296

(AG1296)

Cat. No.: HY-13894

Tyrphostin AG1296 is a potent and selective inhibitor of **platelet-derived growth factor receptor (PDGFR)**, with an **IC_{50}** of 0.8 μM.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg